Diazoxide Capsule
Diazoxide is a compounded formulation containing Diazoxide, prepared by Mixlab for veterinary use. Available by prescription.
Use as directed by your veterinarian.
The uses and pharmacology described below reflect the FDA-approved labeling for this active ingredient; your veterinarian determines whether and how they apply to your animal's treatment plan.
Veterinarians most commonly consider diazoxide for patients presented with insulin-secreting tumors of the pancreas, known as insulinomas. It is frequently discussed in the context of metabolic health when medical management is prioritized or when surgical intervention is not a clinical objective. The decision to initiate diazoxide is typically based on diagnostic findings such as persistent hypoglycemia (low blood sugar) alongside inappropriately elevated serum insulin levels.
At a pharmacological level, diazoxide acts by inhibiting the release of insulin from the pancreatic beta cells. It achieves This mechanism by opening ATP-sensitive potassium channels in the cell membrane, which leads to membrane hyperpolarization and prevents the calcium influx necessary for insulin secretion. Additionally, diazoxide manages blood glucose levels by stimulating the release of catecholamines and inhibiting the peripheral utilization of glucose. By delivering this specific pharmacological influence, the medication provides a method for managing the physiological environment of the pancreas and stabilizing blood sugar concentrations. Your veterinarian will determine the clinical appropriateness of diazoxide based on your pet’s diagnostic profile, physical examination and specific health history.
Prescription only. Use only under the direction of a licensed veterinarian. This information is not a substitute for veterinary diagnosis, prescribing or monitoring. Compounded drugs are not approved by the FDA for safety or effectiveness.
Commonly observed effects following the administration of diazoxide include localized digestive changes such as vomiting, diarrhea or a temporary decrease in appetite. Some animals may exhibit behavioral shifts including lethargy or increased thirst (polydipsia). Because diazoxide can influence cardiovascular and renal function, your veterinarian will monitor for observational signs of fluid retention, such as localized swelling (edema) or shifts in breathing patterns. Owners should monitor their pet for any unusual changes in energy levels or significant shifts in urination habits and contact their veterinarian promptly with any concerns.
This medication is typically used with extra caution or avoided in patients with known cardiovascular disease, congestive heart failure or severe renal impairment. It is also carefully evaluated in pets with pre-existing electrolyte abnormalities or those presented with liver disease. Significant interactions can occur if diazoxide is administered concurrently with specific diuretics, such as thiazides or other medications that influence blood sugar levels or protein binding. Your veterinarian is the right person to provide guidance on the necessary duration of use and the most appropriate monitoring schedule to ensure the management approach remains suitable for your pet's metabolic needs.
Yes. Diazoxide is a prescription medication and can only be dispensed by a licensed pharmacy upon receipt of a valid authorization from a licensed veterinarian. Mixlab verifies all legal authorizations before any medication is prepared or shipped to your home.
Yes. While diazoxide is available in certain commercial capsule and liquid formats for humans, Mixlab specializes in compounding the active ingredient into customized strengths and flavored dosage forms—such as flavored oral liquids—to suit the specific needs of dogs and cats. The decision between a commercial and compounded product rests with the prescribing veterinarian.
Veterinarians discuss diazoxide for insulinomas because it is used in the context of managing insulin secretion from the tumor. Its mechanism provides a method for reducing the risk of low blood sugar, which is a clinical priority for pets presented with this type of pancreatic challenge.
While your pet is receiving diazoxide, you should monitor for observational signs of low blood sugar such as weakness, tremors, coordination changes or fainting. If you notice any of these signs, you should contact your veterinarian immediately for a clinical review of your pet's management approach.
Veterinarians often recommend administering diazoxide with a meal to manage the risk of localized digestive upset. Giving the medication with food can help ensure it is better tolerated by your pet's gastrointestinal system during the course of management.
